KR102627370B1 - 쇼그렌 증후군의 치료에 사용하기 위한 특정 트리플루오로에틸 퀴놀린 유사체 - Google Patents

쇼그렌 증후군의 치료에 사용하기 위한 특정 트리플루오로에틸 퀴놀린 유사체 Download PDF

Info

Publication number
KR102627370B1
KR102627370B1 KR1020177031275A KR20177031275A KR102627370B1 KR 102627370 B1 KR102627370 B1 KR 102627370B1 KR 1020177031275 A KR1020177031275 A KR 1020177031275A KR 20177031275 A KR20177031275 A KR 20177031275A KR 102627370 B1 KR102627370 B1 KR 102627370B1
Authority
KR
South Korea
Prior art keywords
syndrome
sjögren
trifluoroethyl
treatment
certain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177031275A
Other languages
English (en)
Korean (ko)
Other versions
KR20170140245A (ko
Inventor
로저 앤소니 앨런
프란체스카 바론
윌리엄 앤소니 페이
사바 나야르
Original Assignee
유씨비 바이오파마 에스알엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유씨비 바이오파마 에스알엘 filed Critical 유씨비 바이오파마 에스알엘
Publication of KR20170140245A publication Critical patent/KR20170140245A/ko
Application granted granted Critical
Publication of KR102627370B1 publication Critical patent/KR102627370B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020177031275A 2015-04-21 2016-04-20 쇼그렌 증후군의 치료에 사용하기 위한 특정 트리플루오로에틸 퀴놀린 유사체 Active KR102627370B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1506786.1 2015-04-21
GBGB1506786.1A GB201506786D0 (en) 2015-04-21 2015-04-21 Therapeutic use
PCT/EP2016/058810 WO2016170014A1 (en) 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome

Publications (2)

Publication Number Publication Date
KR20170140245A KR20170140245A (ko) 2017-12-20
KR102627370B1 true KR102627370B1 (ko) 2024-01-18

Family

ID=53298950

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177031275A Active KR102627370B1 (ko) 2015-04-21 2016-04-20 쇼그렌 증후군의 치료에 사용하기 위한 특정 트리플루오로에틸 퀴놀린 유사체

Country Status (27)

Country Link
US (1) US10493074B2 (enExample)
EP (1) EP3285772B1 (enExample)
JP (1) JP6721606B2 (enExample)
KR (1) KR102627370B1 (enExample)
CN (1) CN107530344B (enExample)
AR (1) AR105552A1 (enExample)
AU (1) AU2016251236B2 (enExample)
BR (1) BR112017020591B8 (enExample)
CA (1) CA2981631C (enExample)
CL (1) CL2017002669A1 (enExample)
CO (1) CO2017010573A2 (enExample)
CY (1) CY1122572T1 (enExample)
DK (1) DK3285772T3 (enExample)
EA (1) EA032432B1 (enExample)
ES (1) ES2763335T3 (enExample)
GB (1) GB201506786D0 (enExample)
HR (1) HRP20192273T1 (enExample)
HU (1) HUE047162T2 (enExample)
IL (1) IL254766B (enExample)
LT (1) LT3285772T (enExample)
MX (1) MX2017013148A (enExample)
MY (1) MY192972A (enExample)
PL (1) PL3285772T3 (enExample)
PT (1) PT3285772T (enExample)
SG (1) SG11201707789YA (enExample)
SI (1) SI3285772T1 (enExample)
WO (1) WO2016170014A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012032334A1 (en) * 2010-09-08 2012-03-15 Ucb Pharma S.A. Quinoline and quinoxaline derivatives as kinase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20161751T1 (hr) * 2004-05-13 2017-04-07 Icos Corporation Kinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
CN101715453B (zh) * 2007-03-23 2012-06-27 安姆根有限公司 杂环化合物及其应用
EP3444242A3 (en) * 2009-11-05 2019-03-20 Rhizen Pharmaceuticals S.A. Novel benzopyran kinase modulators
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
PL3008053T3 (pl) * 2013-06-14 2018-08-31 Gilead Calistoga Llc Inhibitory 3-kinazy fosfatydyloinozytolu

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012032334A1 (en) * 2010-09-08 2012-03-15 Ucb Pharma S.A. Quinoline and quinoxaline derivatives as kinase inhibitors

Also Published As

Publication number Publication date
BR112017020591B1 (pt) 2023-02-07
CL2017002669A1 (es) 2018-05-11
CY1122572T1 (el) 2021-01-27
CA2981631A1 (en) 2016-10-27
BR112017020591A2 (pt) 2018-07-03
CO2017010573A2 (es) 2018-03-09
EP3285772A1 (en) 2018-02-28
AU2016251236B2 (en) 2018-06-14
IL254766B (en) 2020-05-31
CN107530344B (zh) 2020-03-17
EP3285772B1 (en) 2019-10-02
ES2763335T3 (es) 2020-05-28
LT3285772T (lt) 2020-01-10
PT3285772T (pt) 2020-01-14
JP6721606B2 (ja) 2020-07-15
HRP20192273T1 (hr) 2020-03-06
MX2017013148A (es) 2018-02-21
JP2018513862A (ja) 2018-05-31
SI3285772T1 (sl) 2020-02-28
PL3285772T3 (pl) 2020-05-18
AR105552A1 (es) 2017-10-18
DK3285772T3 (da) 2020-01-13
IL254766A0 (en) 2017-12-31
AU2016251236A1 (en) 2017-11-09
EA201792318A1 (ru) 2018-05-31
BR112017020591B8 (pt) 2023-05-16
US20180092921A1 (en) 2018-04-05
KR20170140245A (ko) 2017-12-20
WO2016170014A1 (en) 2016-10-27
HUE047162T2 (hu) 2020-04-28
GB201506786D0 (en) 2015-06-03
US10493074B2 (en) 2019-12-03
CN107530344A (zh) 2018-01-02
MY192972A (en) 2022-09-20
SG11201707789YA (en) 2017-11-29
EA032432B1 (ru) 2019-05-31
CA2981631C (en) 2023-02-21

Similar Documents

Publication Publication Date Title
EP1663185B1 (en) Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
AU2014249456B2 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
JP2022058443A (ja) 全身性エリテマトーデスの治療のための３－（４－（（４－（モルホリノメチル－ベンジル）オキシ）－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン
WO2009102021A1 (ja) 骨髄由来幹細胞、前駆細胞機能賦活による網膜疾患治療
He et al. PKHB1 peptide induces antiviral effects through induction of immunogenic cell death in herpes simplex keratitis
KR102627370B1 (ko) 쇼그렌 증후군의 치료에 사용하기 위한 특정 트리플루오로에틸 퀴놀린 유사체
WO2011131705A1 (en) Treatment of multiple sclerosis with masitinib
US10548870B2 (en) Method for treating multiple sclerosis
US20210382037A1 (en) Identification and use of cytotoxic t lymphocyte (ctl) antigen-specific target cell killing enhancer agents
Wang et al. KGF-2 Alleviates Dry Eye Disease by Regulating the HMGB1/TLR4 Pathway
CN114748629A (zh) Ccl6/15/23在诊断过敏性气道炎症中的应用
JP2025513444A (ja) 自己免疫性皮膚疾患の治療
EP4228615A1 (en) Method of preventing kidney injury disruption of intestinal lymphatics
JP2019123688A (ja) 重症筋無力症の予防または治療剤としてのバルプロ酸およびその塩

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171027

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210416

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230922

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240109

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240116

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240116

End annual number: 3

Start annual number: 1

PG1601 Publication of registration